Pembrolizumab plus belzutifan improves disease-free survival in high-risk kidney cancer after surgery

Durvalumab plus tremelimumab temporarily reduces QoL in resected renal cell carcinoma patients

Patients with non-metastatic HSPC prefer ARPI-based therapy over androgen deprivation alone

Enzalutamide plus leuprolide achieves durable PSA suppression after treatment suspension

Neoadjuvant cabozantinib plus nivolumab before cytoreductive nephrectomy shows promising responses in metastatic clear cell RCC

ASCO GU 2026: Updates in renal cancer

ASCO GU 2026: Updates in bladder cancer

ASCO GU 2026: Updates in metastatic prostate cancer

ASCO GU 2026: Updates in localised prostate cancer

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma

Tepotinib in second line NSCLC treatment